Chondrosamine Neo capsules №10х6

Name:

Description:
Capsules hard gelatinous cylindrical shape with hemispherical ends with a white body and a red-brown cap. The main active ingredient Chondroitin sulfate + glucosamine + ibuprofen Release form Capsules Dosage 60 pcs. Indications for use For short-term relief of pain and other symptoms of inflammation during exacerbation of osteoarthritis, osteoarthritis, degenerative-dystrophic diseases of the knee and hip joints and spine. Dosing and Administration For adults, take 1-2 capsules 2-3 times a day after meals. Capsules are taken orally with a small amount of water. The maximum duration of admission should not exceed 20 days. After a decrease in severe pain, the patient can continue treatment with combined agents containing glucosamine hydrochloride and chondroitin sulfate. Use during pregnancy and lactation Use is contraindicated. Fertility: There is evidence that drugs that inhibit cyclooxygenase/prostaglandin synthesis can adversely affect the reproductive capacity of women by affecting the ovulation process. After discontinuation, this effect is reversible. Precautions: Patients with a known seafood allergy are advised to take Chondrosamine Neo with caution. Glucosamine hydrochloride Before use, you should consult your doctor to exclude the presence of joint diseases for which other methods of treatment are provided. In patients with impaired glucose tolerance, monitoring of blood glucose levels is necessary and, if necessary, it is recommended to determine the need for insulin before starting treatment and periodically during treatment. In patients with known risk factors for cardiovascular disease, it is recommended to monitor blood lipid levels, as in some cases hypercholesterolemia was observed in patients treated with glucosamine. Exacerbation of asthma symptoms due to glucosamine administration has been reported (symptoms disappeared shortly after glucosamine administration was discontinued). Patients with asthma should be aware of the possible worsening of symptoms. Use the drug with caution in bronchial asthma and diabetes mellitus. When using the drug in patients with impaired glucose tolerance, severe hepatic and renal insufficiency, medical supervision is necessary. Ibuprofen Gastrointestinal Precautions: The use of Chondrosamine Neo together with non-steroidal anti-inflammatory drugs (NSAIDs), including selective cyclooxygenase-2 inhibitors, should be avoided. The manifestation of side effects can be minimized by using the lowest effective dose for the shortest duration of use necessary to improve the condition. Elderly Patients Elderly patients are particularly prone to developing side effects with NSAIDs and careful monitoring is recommended. Gastrointestinal bleeding, peptic ulcer disease and perforation of the ulcer In connection with the use of NSAIDs, gastrointestinal bleeding, ulcers or perforation of ulcers, which can be life-threatening, have been reported throughout the treatment period, both with the onset of warning symptoms and without them. , and also regardless of the presence of severe pathology from the gastrointestinal tract in history. The risk of developing gastrointestinal bleeding, ulceration or perforation increases with increasing dose of NSAIDs in patients with a history of peptic ulcer, especially complicated by bleeding or perforation, as well as in elderly patients. Treatment of these patients should begin with the lowest possible dose. For these patients, and those requiring concomitant therapy with low-dose aspirin or other medicinal products that increase the risk of gastrointestinal disturbances, combination therapy with protective agents (eg, misoprostol or inhibitors) should be considered. proton pump). Patients with a history of gastrointestinal toxicity, particularly the elderly, should report any unusual gastrointestinal symptoms (particularly gastrointestinal bleeding), especially during the initial stages of treatment. When taken concomitantly with drugs that can increase the risk of ulcers or bleeding, special care should be taken. These drugs include oral corticosteroids, anticoagulants such as warfarin, selective serotonin reuptake inhibitors, or antiplatelet agents such as aspirin. In the event of gastrointestinal bleeding or ulcers while using Chondrosamine Neo, drug treatment should be discontinued. NSAIDs, which include ibuprofen, should be used with caution in patients with a history of gastrointestinal diseases (ulcerative colitis, Crohn’s disease), as they can exacerbate these diseases. Effects on the cardiovascular system and cerebral circulation The drug should be used with caution in patients with arterial hypertension and / or heart failure in history (a consultation with a doctor or a pharmacy worker is required), since in the treatment of NSAIDs there have been cases of fluid retention in tissues, arterial hypertension and edema development. According to the results of clinical studies and epidemiological data, the use of ibuprofen, especially at high doses (2400 mg per day), as well as with prolonged therapy, may be associated with a slight increase in the risk of developing conditions caused by arterial thrombosis (for example, myocardial infarction or stroke). In general, data obtained from epidemiological studies indicate that low doses of ibuprofen (eg, < 1200 mg per day) are not associated with an increased risk of myocardial infarction. In patients with uncontrolled hypertension, congestive heart failure, confirmed coronary artery disease, peripheral arterial and/or cerebrovascular disease, ibuprofen should only be given after a thorough assessment of the situation. The same questions should be addressed before initiating long-term treatment in patients with cardiovascular risk factors (eg, hypertension, hyperlipidemia, diabetes mellitus, smoking). Skin reactions There are reports that in very rare cases, the development of severe skin reactions, sometimes fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis, has been associated with the use of NSAIDs. They appear to be most at risk early in treatment, as in most patients, these reactions developed in the first month of therapy. At the first appearance of a skin rash, mucosal lesions or any other sign of hypersensitivity, the drug should be discontinued. Other indications The drug Chondrosamine Neo can be used only after a thorough assessment of the benefit / risk ratio in the following cases: with systemic lupus erythematosus (SLE) and mixed collagenoses - the risk of aseptic meningitis increases. Particularly careful medical supervision is required: in case of violations of the gastrointestinal tract or in the presence of a history of chronic inflammatory bowel diseases (ulcerative colitis, Crohn's disease); with high blood pressure or heart failure; in case of impaired renal function (because patients with pre-existing kidney disease may develop acute renal dysfunction); with dehydration; with violations of liver function; immediately after major surgery; with allergies to pollen, nasal polyps and chronic obstructive respiratory diseases, since these patients are at increased risk of allergic reactions (these reactions can manifest as asthma attacks (so-called analgesic asthma), Quincke's edema or urticarial rash); with allergies to other drugs, since such patients have an increased risk of hypersensitivity reactions, including during treatment with the drug Chondrosamine Neo. Severe acute hypersensitivity reactions (eg, anaphylactic shock) are extremely rare. When the first signs of hypersensitivity reactions appear after taking the drug, treatment should be stopped immediately. Necessary medical measures in accordance with the symptoms should be taken by qualified specialists. Ibuprofen may temporarily suppress platelet function (platelet aggregation). In this regard, it is necessary to establish a thorough medical supervision of patients with bleeding disorders. With long-term use of the drug Chondrosamine Neo, regular monitoring of liver function, kidney function, and general blood count is necessary. With prolonged use of painkillers, headaches may occur, which cannot be treated by increasing the dose of these drugs. In general, frequent, "habitual" use of painkillers, especially the use of combinations of several painkillers, can lead to the development of irreversible kidney damage, accompanied by a risk of kidney failure ("analgesic" nephropathy). In special cases, against the background of chickenpox, severe infectious complications from the skin and soft tissues can develop. To date, it is impossible to completely exclude the possibility of an association between NSAIDs and the development of such infectious complications. Therefore, with chicken pox, it is recommended to avoid taking the drug Chondrosamine Neo. When drinking alcohol during the treatment of NSAIDs, it is possible to increase the risk of side effects, in particular, from the gastrointestinal tract or the central nervous system. Due to the presence of dyes (E-104, E-129, E-133), taking the drug may cause allergic reactions. The risk of allergy is higher in the presence of an allergy to acetylsalicylic acid. Interaction with other drugs Glucosamine hydrochloride is compatible with non-steroidal anti-inflammatory drugs, paracetamol and glucocorticosteroids. Increased prothrombotic time has been reported with coumarin anticoagulants (eg warfarin and acetocoumarol). Therefore, in patients receiving coumarin anticoagulants, it is necessary to carefully monitor the start and end of glucosamine therapy. Concurrent treatment with glucosamine may increase the absorption and serum concentration of tetracycline, but the clinical significance of this interaction is unlikely. Chondrosamine sulfate. Interactions are not described. Ibuprofen (like other NSAIDs) requires special care when taken with the following drugs: Other NSAIDs, including salicylates: simultaneous use of several different NSAIDs may increase the risk of gastrointestinal ulcers and bleeding due to a synergistic effect. In this regard, the simultaneous use of ibuprofen and other NSAIDs is not recommended. Digoxin, phenytoin, lithium: the use of the drug Chondrosamine Neo simultaneously with digoxin, phenytoin or lithium may increase the plasma concentration of these drugs. Control of the concentration of lithium, digoxin and phenytoin in plasma, when used correctly, is usually not required (maximum within 4 days). Diuretics, ACE inhibitors, beta-blockers and angiotensin II antagonists: NSAIDs may reduce the effectiveness of diuretics and other antihypertensive drugs. In some patients with impaired renal function (eg, patients who are dehydrated or elderly patients with limited renal function), co-administration of ACE inhibitors, beta-blockers or angiotensin II antagonists, and substances that suppress the cyclooxygenase system may cause further decrease in kidney function (up to acute renal failure), which is usually reversible. Therefore, the joint use of these drugs should be prescribed with caution, especially in elderly patients. Patients should receive sufficient fluids. Both after the start of joint therapy, and subsequently, renal function should be carefully monitored periodically. With the simultaneous administration of ibuprofen and potassium-sparing diuretics, hyperkalemia may develop. Corticosteroids: increased risk of gastrointestinal ulcers or bleeding. Platelet aggregation inhibitors and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding. Acetylsalicylic acid in low doses: experimental data suggest that when used simultaneously with ibuprofen, there may be an effect of inhibiting the effect of low doses of acetylsalicylic acid on platelet aggregation. However, the paucity of data and the existing doubts about the applicability of the findings from ex vivo studies to the clinical setting suggest that no definitive conclusions can be drawn for regular ibuprofen use, and that any clinically significant effects are considered unlikely for occasional ibuprofen use. . Methotrexate: Taking ibuprofen within 24 hours before and after taking methotrexate may lead to an increase in the concentration of methotrexate and an increase in its toxic effect. Cyclosporine: The simultaneous use of certain NSAIDs increases the risk of impaired renal function due to the action of cyclosporine. The appearance of this effect is not excluded in the combination of cyclosporine with ibuprofen. Anticoagulants: NSAIDs may increase the effect of anticoagulants such as warfarin. Sulfonylureas: The results of clinical studies indicate the presence of the interaction of NSAIDs with antidiabetic drugs (sulfonylurea drugs). Despite the fact that the interaction of ibuprofen with sulfonylurea drugs has not yet been described, while taking these drugs for prophylactic purposes, it is recommended to control blood sugar levels. Tacrolimus: concomitant use increases the risk of nephrotoxicity. Zidovudine: There is evidence that the simultaneous use of zidovudine and ibuprofen in HIV-infected patients with hemophilia increases the risk of developing hemarthroses and hematomas. Probenecid and sulfinpyrazone: medicines containing probenecid and sulfinpyrazone can delay the excretion of ibuprofen from the body. Contraindications Hypersensitivity to any of the active or excipients; a history of bronchospasm, asthma, rhinitis or urticaria after taking acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs); hematopoietic disorders of unknown origin; present or past recurrent peptic ulcer/bleeding (two or more separate episodes of confirmed peptic ulcer or bleeding); a history of gastrointestinal bleeding or ulcer perforation associated with previous NSAID therapy; cerebrovascular bleeding or other bleeding currently present; severe impairment of liver or kidney function (creatinine clearance < 30 ml / min); severe heart failure; last trimester of pregnancy; children and adolescents under 18 years of age. Composition One capsule contains chondroitin sulfate - 200 mg; glucosamine hydrochloride - 250 mg, ibuprofen - 100.0 mg. Excipients: crospovidone (type A), anhydrous colloidal silicon dioxide, magnesium stearate, microcrystalline cellulose. The composition of the capsule shell: gelatin, glycerin, purified water, titanium dioxide E-171, sodium lauryl sulfate, dyes: charming red E-129, quinoline yellow E-104, brilliant blue E-133. Overdose For glucosamine hydrochloride and chondroitin sulfate, overdose symptoms are unknown. With an established overdose, treatment is symptomatic. Ibuprofen. Overdose symptoms: disorders of the nervous system - headache, dizziness, fainting and loss of consciousness (with myoclonic convulsions in children), as well as abdominal pain, nausea and vomiting. Perhaps the development of gastrointestinal bleeding, as well as functional disorders of the liver and kidneys. Decreased blood pressure, respiratory depression, and cyanosis are also possible. Therapeutic measures in case of overdose. There is no specific antidote for ibuprofen. Treatment depending on the degree, level and clinical symptoms of intoxication in accordance with generally accepted practice in intensive care. Side effect The frequency of adverse reactions indicated below was determined using the following note: very often (≥ 1/10), often (≥ 1/100 - < 1/10), infrequently (≥ 1/1000 - < 1/100), rarely (≥ 1/10000 - < 1/1000), very rare (< 1/10000), unknown (cannot be determined from the available data). Glucosamine hydrochloride Gastrointestinal disorders. Often: discomfort and pain in the abdomen, dyspepsia, constipation, nausea, flatulence, diarrhea. Skin and subcutaneous tissue disorders. Infrequently: itching, erythema, skin rash. Not known: hair loss. Immune system disorders. Uncommon: allergic reactions, bronchial asthma. Nervous system disorders. Often: headache, drowsiness, fatigue. Not known: dizziness. Violations of the organs of vision. Uncommon: blurred vision. Blood disorders. Infrequently: elevated blood glucose levels. Chondroitin sulfate From the skin and subcutaneous tissue: there are reports of isolated cases of erythema, urticaria, dermatitis, maculopapular rash with or without itching, and / or edema. From the gastrointestinal tract: rare cases of nausea, vomiting. Ibuprofen The following side effects have been observed during treatment with ibuprofen, including during long-term treatment with high doses in patients suffering from rheumatism. The established frequency, including very rare cases, refers to short-term treatment in daily doses up to 1200 mg of ibuprofen for oral dosage form and up to 1800 mg for suppositories. The following side effects of the drug mainly vary depending on the dosage and individual characteristics of the patients. The most common - from the gastrointestinal tract. Thus, it is possible to develop peptic ulcer, perforation or gastrointestinal bleeding, sometimes fatal, especially in elderly patients. There are reports of nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, tarry stools, ulcerative stomatitis, as well as exacerbation of ulcerative colitis and Crohn's disease after taking ibuprofen. Rarely, gastritis has been reported. The risk of gastrointestinal bleeding depends on the dose and duration of ibuprofen use. It was reported about the development of edema, increased blood pressure and the development of heart failure during the treatment of NSAIDs. According to clinical trials and epidemiological data, the use of ibuprofen, especially at high doses (2400 mg per day / 24 capsules), as well as during long-term therapy, may be associated with a slight increase in the risk of developing conditions caused by arterial thrombosis (for example, myocardial infarction or stroke). Heart disorders. Very rare: palpitations, heart failure, myocardial infarction. Blood and lymphatic disorders. Very rarely: hematopoietic disorders (anemia, leukopenia, thrombocytopenia, pancytopenia, agranulocytosis). The first signs are fever, sore throat, superficial sores in the mouth, flu-like symptoms, severe weakness, nosebleeds, and bleeding into the skin. With long-term treatment with the drug, a complete blood count should be carried out regularly. Nervous system disorders. Uncommon: central nervous system disorders such as headache, dizziness, insomnia, agitation, irritability or fatigue. Violations of the organs of vision. Sometimes: visual disturbances. Ear and labyrinth disorders. Rare: tinnitus. Gastrointestinal disorders. Often: complaints of heartburn, abdominal pain, nausea, vomiting, flatulence, diarrhea, constipation, and minor gastrointestinal bleeding, which in some cases can lead to the development of anemia. Uncommon: gastric / duodenal ulcers with a possibility of bleeding and perforation. Ulcerative stomatitis, exacerbation of nonspecific ulcerative colitis or Crohn's disease, gastritis. Very rare: esophagitis, pancreatitis, formation of diaphragm-like intestinal structures. In the event of severe pain in the upper abdomen, tarry stools or bloody vomiting, you should immediately stop taking Chondrosamine Neo and consult a doctor. Renal and urinary tract disorders. Very rarely: the appearance of edema, especially in patients with arterial hypertension or renal insufficiency; nephrotic syndrome; interstitial nephritis, which may be accompanied by acute renal failure. In rare cases, damage to the kidney tissue (necrosis of the renal papillae) with an increase in the concentration of uric acid in the blood. Therefore, regular monitoring of kidney function is necessary. Violations of the skin and subcutaneous fat. Very rare: bullous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. With chickenpox, in exceptional cases, severe skin infections and complications from soft tissues may develop (see also "Infectious and parasitic diseases"). Infectious and parasitic diseases. Very rarely, cases of exacerbation of inflammatory processes of infectious origin (for example, the development of necrotizing fasciitis) associated with the use of non-steroidal anti-inflammatory drugs have been described. Perhaps this is due to the mechanism of action of NSAIDs. If signs of infection or their increase appear during treatment with Chondrosamine Neo, it is recommended to immediately consult a doctor. In this case, it is necessary to check whether there are indications for antibiotic therapy of the infection. Very rarely, during treatment with ibuprofen, symptoms of aseptic meningitis were observed: stiff neck, headache, nausea, vomiting, fever or clouding of consciousness. Patients with autoimmune diseases (systemic lupus erythematosus, mixed collagenosis) are predisposed to the occurrence of such conditions. vascular disorders. Very rare: arterial hypertension. Immune system disorders. Sometimes: hypersensitivity reactions, accompanied by skin rash and itching, as well as asthma attacks (in some cases with a drop in blood pressure). Patients are advised in such cases to immediately stop taking the drug and consult a doctor. Very rare: severe general hypersensitivity reactions in the form of swelling of the face, tongue and larynx with narrowing of the airways, respiratory distress syndrome, heart palpitations, drop in blood pressure up to life-threatening shock. If any of these symptoms occur, even when the drug is used for the first time, urgent medical attention is needed. Liver and biliary tract disorders. Very rare: abnormal liver function, liver damage, especially with long-term therapy, liver failure, acute hepatitis. Mental disorders: Very rarely: psychotic reactions, depression. Storage conditions Buy Chondrosamine Neo capsules No. 10x6 Price for Chondrosamine Neo capsules No. 10x6